Castle Biosciences, Inc. (CSTL)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Castle Biosciences, Inc. (CSTL)
Go deeper and ask any question about CSTL
Company Performance
Current Price
as of Sep 13, 2024$31.18
P/E Ratio
N/A
Market Cap
$864.83M
Description
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.
Metrics
Overview
- HQFriendswood, TX
- SectorHealth Technology
- IndustryMedical Specialties
- TickerCSTL
- Price$31.18+1.63%
Trading Information
- Market Cap$864.83M
- Float93.58%
- Average Daily Volume (1m)340,560
- Average Daily Volume (3m)410,693
- EPS-$0.12
Company
- Revenue$287.59M
- Rev Growth (1yr)73.53%
- Net Income$8.92M
- Gross Margin80.20%
- EBITDA Margin9.61%
- EBITDA$8.36M
- EV$391.13M
- EV/Revenue1.36
- P/EN/A
- P/S3.12